For research use only. Not for therapeutic Use.
Bucolome is a CYP2C9 inhibitor, used as an uricosuric agent or anti-inflammatory agent.
Bucolome is a potent mixed-type inhibitor for (S)-warfarin 7-hydroxylation, with Ki of 8.2 and 20.2 μM, respectively[1].
| Catalog Number | I013471 |
| CAS Number | 841-73-6 |
| Synonyms | 5-butyl-1-cyclohexyl-1,3-diazinane-2,4,6-trione |
| Molecular Formula | C14H22N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19) |
| InChIKey | DVEQCIBLXRSYPH-UHFFFAOYSA-N |
| SMILES | CCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2 |
| Reference | [1]. Takahashi H, et al. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos. 1999 Oct;27(10):1179-86. |
